Media Centre

Featured Media Release
 

18 Feb 2014 - Poppy Crop Security Update

GlaxoSmithKline (GSK) is aware that there may be an increased concern in poppy crop security following recent media reports.

 
 

Media Releases


GSK innovation helps relieve smokers cravings in 50 seconds

GSK Australia launched today a new innovative product Nicabate Oral Strips that relieve the urge to smoke in just 50 seconds. Nicabate Oral Strips are the first and only nicotine oral strips in the country.

16/04/2014

 

Illuminate your smile with the new Macleans® High Definition™ White range

Whether having a laugh with friends, showcasing ideas at a business meeting or embarking on a first date with that special someone – an illuminated smile can make you look and feel your best at all times. So light-up your day and ensure you're...

15/04/2014

 

GSK brings New Zealand to the forefront in new Panadol® brand campaign

A Kiwi father and son will star in a brand new Panadol campaign to be aired on television screens globally, bringing New Zealand to the forefront of what is a new direction for the trusted brand.

28/03/2014

 

GSK RECALLS NICOTINE LOZENGES FROM WAREHOUSES AND DISTRIBUTORS

GSK is in the process of voluntarily recalling from warehouses and distributors a number of batches of nicotine lozenges sold globally, after we detected manufacturing issues affecting some batches. In some cases, the lozenges were larger or...

26/03/2014

 

New PBS listing for patients with advanced soft tissue sarcoma

Treatment options for advanced Soft Tissue Sarcoma (STS) have been broadened with a new Pharmaceutical Benefits Scheme (PBS) listing for Votrient® (pazopanib hydrochloride)1 providing a targeted treatment option for physicians and their patients.

14/03/2014

 

TGA approves GSK’s combination of TAFINLAR®(dabrafenib) and MEKINIST® (trametinib)

GSK Australia announced today that the Therapeutics Goods Administration (TGA) has approved the combination of two oral targeted therapies, MEKINIST (trametinib) and TAFINLAR (dabrafenib), for the treatment of patients with BRAF V600 mutation...

06/03/2014

 

Supply of Varilrix® and Priorix-Tetra® resumes

Supply of Varilrix® and Priorix-Tetra® will resume gradually by

05/03/2014

 

Poppy Crop Security Update

GlaxoSmithKline (GSK) is aware that there may be an increased concern in poppy crop security following recent media reports.

18/02/2014

 

Supply of Varilrix® and Priorix-Tetra®

GSK recently identified a global manufacturing issue relating to some of our varicella-containing vaccines which has resulted in temporary disruptions to supply of Varilrix® and Priorix-Tetra®.

23/01/2014

 

GSK announces changes to its global sales and marketing practices

GSK announced today changes to the way products are marketed and sold to healthcare professionals to further align the company’s activities with the interests of patients.

17/12/2013

1 2 3 4 5 6 7 8 9 10 11 >